1. Hardy, M. L., Coulter, I., Morton, S. C., Favreau, J., Venuturupalli, S., Chiappelli, F., Rossi, F., Orshansky, G., Jungvig, L. K., Roth, E. A., Suttorp, M. J., & Shekelle, P. (2003). S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment, 64, 1–3.
2. Zano, S. P., Bhansali, P., Luniwal, A., & Viola, R. E. (2013). Alternative substrates selective for S-adenosylmethionine synthetases from pathogenic bacteria. Archives of Biochemistry and Biophysics, 536, 64–71.
3. Miller, S. A., & Bandarian, V. (2019). Analysis of electrochemical properties of S-adenosyl-l-methionine and implications for its role in radical SAM enzymes. Journal of the American Chemical Society, 141, 11019–11026.
4. Mato, J. M., & Lu, S. C. (2007). Role of S-adenosyl-L-methionine in liver health and injury. Hepatology, 45, 1306–1312.
5. Galizia, I., Oldani, L., Macritchie, K., Amari, E., Dougall, D., Jones, T. N., Lam, R. W., Massei, G. J., Yatham, L. N., & Young, A. H. (2016). S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database of Systematic Reviews, 10, CD011286.